We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Gilead's Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide Meets Primary 48-Week Objective in Phase 3 Study.
- Abstract
The article discusses a phase 3 study by the biotechnology firm Gilead Sciences Inc. to evaluate the efficacy of a fixed-dose combination of emtricitabine and tenofovir alafenamide for the treatment of HIV-1 infection, which showed virologic suppression rate same as tenofovir disoproxil fumarate.
- Subjects
HIV infections; THERAPEUTICS; EMTRICITABINE-tenofovir; GILEAD Sciences Inc.
- Publication
Clinical Infectious Diseases, 2015, Vol 61, Issue 10, pii
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/civ853